1 Executive Summary
2 Market Introduction
2.1 Scope Of Study 32
2.2 Research Objective 32
2.3 List Of Assumptions 32
2.4 Market Structure 33
3 Research Methodology
3.1 Research Process 35
3.2 Primary Research 36
3.3 Secondary Research 37
3.4 Market Size Estimation 37
3.5 Forecast Model 38
4 Market Dynamics
4.1 Introduction 40
4.2 Drivers 41
4.2.1 Increasing Awareness Along With The High Prevalence Of The Avascular Necrosis Disease 41
4.2.2 Rising Preference Of Surgeries To Cure Osteonecrosis 41
4.2.3 Rising Preference Of Bone Grafting Surgical Procedures With The Less Pain Substitute Procedures 41
4.2.4 Consolidation Of Large Healthcare Providers In The U.S. 42
4.2.5 Technological Advancements In The Development Of Surgical Implants 42
4.3 Restraints 42
4.3.1 The High Cost Of Surgical Procedures And Related Side Effects 42
4.3.2 Worsening Regulatory Landscape And Growing Cost Of Noncompliance In Developed Countries 43
4.4 Opportunities 43
4.4.1 Growing Demand For Non-Invasive Treatments For Faster Recovery 43
4.5 Technology Trends & Assessment 44
4.5.1 Acceptance Of Synthetic Bone-Graft Over Natural Ones 44
4.5.2 Nanotechnology 44
4.5.3 Rising Demand For Incorporating Recombinant DNA Technology In Surgical Implants 44
4.5.4 Development Of Titanium-Foam Implant For Bone Grafting 44
4.5.5 Customized Degradable Implants 44
5 Market Factor Analysis
5.1 Porter’s Five Forces Model 46
5.1.1 Bargaining Power Of Suppliers 46
5.1.2 Bargaining Power Of Buyers 47
5.1.3 Threat Of New Entrants 47
5.1.4 Threat Of Substitutes 47
5.1.5 Intensity Of Rivalry 48
5.2 Value Chain Analysis 48
5.2.1 Research & Development 48
5.2.2 Manufacturing 49
5.2.3 Distribution 49
5.2.4 Marketing & Sales 49
5.2.5 Post-Sales Monitoring 49
5.3 Epidemiology Of Avascular Necrosis 49
6 Avascular Necrosis Market, By Type
6.1 Introduction 54
6.2 Non-Trauma Related Avascular Necrosis 55
6.2.1 Age Group 56
6.2.1.1 Third Decade 57
6.2.1.2 Fifth Decade 57
6.2.2 Causes 58
6.2.2.1 Caisson Disease 59
6.2.2.2 Sickle Cell Anaemia 60
6.2.2.3 Steroid Abuse 60
6.2.2.4 Alcohol Abuse 61
6.3 Trauma-Related Avascular Necrosis 62
7 Avascular Necrosis Market, By Site
7.1 Introduction 64
7.2 Hip Bone 65
7.3 Knee 66
7.4 Shoulder 67
8 Avascular Necrosis Market, By Diagnosis
8.1 Introduction 69
8.2 Imaging 70
8.2.1 X-Ray 72
8.2.2 CT Scan 72
8.2.3 MRI 73
8.2.4 PET 74
8.3 Biopsy 74
9 Avascular Necrosis Market, By Treatment
9.1 Introduction 77
9.2 Medication 78
9.2.1 Medication By NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) 79
9.2.2 Medication By Bisphosphonates 79
9.2.3 Medication By Blood Thinners 80
9.3 Electrical Stimulation 81
9.4 Gene Therapy 82
9.5 Surgery 82
9.5.1 Core Decompression 83
9.5.2 Osteotomy 84
9.5.3 Bone Graft 85
9.5.4 Arthoplasty 85
10 Avascular Necrosis Market, By End-User
10.1 Introduction 88
10.2 Hospitals & Clinics 89
10.3 Diagnostic Centers 90
10.4 Ambulatory Surgical Centers 91
11 Global Avascular Necrosis Market, By Region
11.1 Introduction 93
11.2 Americas 103
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.2.1 North America 112
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.2.1.1 U.S. 123
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.2.1.2 Canada. 131
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.2.2 South America 140
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3 Europe 149
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.1 Western Europe 160
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.1.1 Germany 170
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.1.2 France 179
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.1.3 UK 188
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.1.4 Italy 197
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.1.5 Spain 206
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.1.6 Rest Of Western Europe 215
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.3.2 Eastern Europe 224
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.4 Asia Pacific 232
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.4.1 Japan 243
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.4.2 China 251
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.4.3 India 260
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.4.4 Australia 268
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.4.5 Republic Of Korea 277
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.4.6 Rest Of Asia Pacific 285
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.5 The Middle East & Africa 294
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.5.1.1 Middle East 303
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
11.5.1.2 Africa 313
Avascular Necrosis Market, By Type
Avascular Necrosis Market, By Site
Avascular Necrosis Market, By Diagnosis
Avascular Necrosis Market, By Treatment
Avascular Necrosis Market, By End-User
12 Competitive Landscape
12.1 Introduction 324
12.2 Company Market Share Analysis 325
12.2.1 Introduction 325
12.3 Key Developments 326
13 Company Profiles
13.1 Sanofi 330
13.1.1 Company Overview 330
13.1.2 Financial Overview 330
13.1.3 Products Offering 331
13.1.4 Key Developments 331
13.1.5 SWOT Analysis 331
13.1.6 Key Strategy 331
13.2 Bayer Healthcare AG 332
13.2.1 Company Overview 332
13.2.2 Financial Overview 332
13.2.3 Products Offering 333
13.2.4 Key Developments 333
13.2.5 SWOT Analysis 333
13.2.6 Key Strategy 333
13.3 Boehringer Ingelheim GmbH 334
13.3.1 Company Overview 334
13.3.2 Financial Overview 334
13.3.3 Products Offering 335
13.3.4 Key Developments 335
13.3.5 SWOT Analysis 335
13.3.6 Key Strategy 335
13.4 Pfizer Inc. 336
13.4.1 Company Overview 336
13.4.2 Financial Overview 336
13.4.3 Products Offering 337
13.4.4 Key Developments 337
13.4.5 SWOT Analysis 337
13.4.6 Key Strategy 337
13.5 Merck KGaA 338
13.5.1 Company Overview 338
13.5.2 Financial Overview 338
13.5.3 Products Offering 339
13.5.4 Key Developments 339
13.5.5 SWOT Analysis 339
13.5.6 Key Strategy 339
13.6 Stryker Corporation 340
13.6.1 Company Overview 340
13.6.2 Financial Overview 340
13.6.3 Products Offering 341
13.6.4 Key Developments 341
13.6.5 SWOT Analysis 342
13.6.6 Key Strategy 342
13.7 Medtronic PLC 343
13.7.1 Company Overview 343
13.7.2 Financial Overview 343
13.7.3 Products Offering 344
13.7.4 Key Developments 344
13.7.5 SWOT Analysis 344
13.7.6 Key Strategy 344
13.8 Aurobindo Pharma 345
13.8.1 Company Overview 345
13.8.2 Financial Overview 345
13.8.3 Products Offering 346
13.8.4 Key Developments 346
13.8.5 SWOT Analysis 347
13.8.6 Key Strategy 347
13.9 Integra LifeSciences Corporation 348
13.9.1 Company Overview 348
13.9.2 Financial Overview 348
13.9.3 Products Offering 349
13.9.4 Key Developments 349
13.9.5 SWOT Analysis 349
13.9.6 Key Strategy 349
13.10 Zimmer Biomet Holdings 350
13.10.1 Company Overview 350
13.10.2 Financial Overview 350
13.10.3 Products Offering 351
13.10.4 Key Developments 351
13.10.5 SWOT Analysis 352
13.10.6 Key Strategy 352
13.11 Wright Medical Group N.V. 353
13.11.1 Company Overview 353
13.11.2 Financial Overview 353
13.11.3 Products Offering 354
13.11.4 Key Developments 354
13.11.5 SWOT Analysis 355
13.11.6 Key Strategy 355
13.12 Grifols SA 356
13.12.1 Company Overview 356
13.12.2 Financial Overview 356
13.12.3 Products Offering 357
13.12.4 Key Developments 357
13.12.5 SWOT Analysis 357
13.12.6 Key Strategy 357
13.13 Smith & Nephew 358
13.13.1 Company Overview 358
13.13.2 Financial Overview 358
13.13.3 Products Offering 359
13.13.4 Key Developments 359
13.13.5 SWOT Analysis 360
13.13.6 Key Strategy 360
13.14 Ethicon Inc. 361
13.14.1 Company Overview 361
13.14.2 Financial Overview 361
13.14.3 Products Offering 362
13.14.4 Key Developments 362
13.14.5 SWOT Analysis 363
13.14.6 Key Strategy 363
14 Conclusion
14.1 Key Findings 365
14.1.1 CEO’s Viewpoint 365
14.1.2 Unmet Needs 365
14.1.3 Key Companies To Watch 365
14.1.4 Prediction 365
15 Appendix
15.1 Discussion Blue Print 367
16 List Of Tables
TABLE 1 MARKET SYNOPSIS 30
TABLE 2 LIST OF ASSUMPTIONS 32
TABLE 3 NORTH AMERICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 50
TABLE 4 NORTH AMERICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 50
TABLE 5 SOUTH AMERICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 50
TABLE 6 SOUTH AMERICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 50
TABLE 7 EUROPE PROCEDURE NUMBERS, 2020–2016 (UNITS) 51
TABLE 8 EUROPE PROCEDURE NUMBERS, 2027–2027 (UNITS) 51
TABLE 9 ASIA PACIFIC PROCEDURE NUMBERS, 2020–2016 (UNITS) 51
TABLE 10 ASIA PACIFIC PROCEDURE NUMBERS, 2027–2027 (UNITS) 51
TABLE 11 MIDDLE EAST PROCEDURE NUMBERS, 2020–2016 (UNITS) 52
TABLE 12 MIDDLE EAST PROCEDURE NUMBERS, 2027–2027 (UNITS) 52
TABLE 13 AFRICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 52
TABLE 14 AFRICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 52
TABLE 15 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 54
TABLE 16 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 54
TABLE 17 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 55
TABLE 18 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 56
TABLE 19 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 56
TABLE 20 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP,2020–2027 (USD MILLION) 56
TABLE 21 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION 2020–2027 (USD MILLION) 57
TABLE 22 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION, 2020–2027 (USD MILLION) 57
TABLE 23 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2020–2027 (USD MILLION) 57
TABLE 24 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2020–2027 (USD MILLION) 58
TABLE 25 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2020–2027 (USD MILLION) 58
TABLE 26 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2020–2027 (USD MILLION) 59
TABLE 27 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2020–2027 (USD MILLION) 59
TABLE 28 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2020–2027 (USD MILLION) 59
TABLE 29 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANAEMIA, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 30 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANEMIA, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 31 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 32 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2020–2027 (USD MILLION) 61
TABLE 33 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2020–2027 (USD MILLION) 61
TABLE 34 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2020–2027 (USD MILLION) 61
TABLE 35 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 62
TABLE 36 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 62
TABLE 37 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020–2027 (USD MILLION) 64
TABLE 38 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020–2027 (USD MILLION) 65
TABLE 39 GLOBAL AVASCULAR NECROSIS MARKET FOR HIP BONE, BY REGION, 2020–2027 (USD MILLION) 65
TABLE 40 GLOBAL AVASCULAR NECROSIS MARKET, FOR HIP BONE, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 41 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 42 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 43 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2020–2027 (USD MILLION) 67
TABLE 44 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2020–2027 (USD MILLION) 67
TABLE 45 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020–2027 (USD MILLION) 69
TABLE 46 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020–2027 (USD MILLION) 69
TABLE 47 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 48 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 49 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020–2027 (USD MILLION) 71
TABLE 50 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020–2027 (USD MILLION) 71
TABLE 51 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 52 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY , BY REGION, 2020–2027 (USD MILLION) 72
TABLE 53 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 54 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 55 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 56 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 57 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 58 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 59 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 60 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 61 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2020–2027 (USD MILLION) 77
TABLE 62 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2020–2027 (USD MILLION) 78
TABLE 63 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 64 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 65 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020–2027 (USD MILLION) 79
TABLE 66 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020–2027 (USD MILLION) 79
TABLE 67 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020–2027 (USD MILLION) 80
TABLE 68 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020–2027 (USD MILLION) 80
TABLE 69 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020–2027 (USD MILLION) 80
TABLE 70 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020–2027 (USD MILLION) 81
TABLE 71 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 72 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 73 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 74 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 75 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 76 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 77 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 78 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION , BY REGION, 2020–2027 (USD MILLION) 84
TABLE 79 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY , BY REGION, 2020–2027 (USD MILLION) 84
TABLE 80 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 81 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 82 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 83 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 84 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2020–2027 (USD MILLION) 86
TABLE 85 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 86 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 87 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 88 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 89 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 90 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS , BY REGION, 2020–2027 (USD MILLION) 90
TABLE 91 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2020 2027 (USD MILLION) 91
TABLE 92 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2020–2027 (USD MILLION) 91
TABLE 93 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 93
TABLE 94 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 93
TABLE 95 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 94
TABLE 96 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 94
TABLE 97 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 95
TABLE 98 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 95
TABLE 99 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 95
TABLE 100 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 96
TABLE 101 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 96
TABLE 102 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 96
TABLE 103 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 97
TABLE 104 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 97
TABLE 105 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 97
TABLE 106 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 98
TABLE 107 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 98
TABLE 108 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 98
TABLE 109 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 99
TABLE 110 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 99
TABLE 111 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 99
TABLE 112 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 100
TABLE 113 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 100
TABLE 114 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 100
TABLE 115 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 101
TABLE 116 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 101
TABLE 117 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 101
TABLE 118 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 102
TABLE 119 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 102
TABLE 120 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 102
TABLE 121 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 103
TABLE 122 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 103
TABLE 123 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 104
TABLE 124 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 104
TABLE 125 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 104
TABLE 126 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 105
TABLE 127 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 105
TABLE 128 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 105
TABLE 129 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 106
TABLE 130 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 106
TABLE 131 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 106
TABLE 132 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 106
TABLE 133 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 107
TABLE 134 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 107
TABLE 135 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 107
TABLE 136 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 108
TABLE 137 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 108
TABLE 138 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 108
TABLE 139 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 109
TABLE 140 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 109
TABLE 141 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 109
TABLE 142 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 110
TABLE 143 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 110
TABLE 144 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 110
TABLE 145 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 111
TABLE 146 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 111
TABLE 147 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 111
TABLE 148 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 112
TABLE 149 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 112
TABLE 150 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 112
TABLE 151 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 113
TABLE 152 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 114
TABLE 153 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 114
TABLE 154 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 114
TABLE 155 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 115
TABLE 156 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 115
TABLE 157 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 115
TABLE 158 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 116
TABLE 159 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 116
TABLE 160 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 116
TABLE 161 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 117
TABLE 162 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 117
TABLE 163 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 117
TABLE 164 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 118
TABLE 165 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 118
TABLE 166 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 118
TABLE 167 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 119
TABLE 168 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 119
TABLE 169 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 119
TABLE 170 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 120
TABLE 171 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 120
TABLE 172 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 120
TABLE 173 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 121
TABLE 174 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 121
TABLE 175 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 121
TABLE 176 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 122
TABLE 177 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 122
TABLE 178 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 122
TABLE 179 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 123
TABLE 180 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 123
TABLE 181 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 123
TABLE 182 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 124
TABLE 183 U.S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 124
TABLE 184 U.S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 124
TABLE 185 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 125
TABLE 186 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 125
TABLE 187 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 125
TABLE 188 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 125
TABLE 189 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 126
TABLE 190 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 126
TABLE 191 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 126
TABLE 192 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 127
TABLE 193 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 127
TABLE 194 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 127
TABLE 195 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 128
TABLE 196 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 128
TABLE 197 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 128
TABLE 198 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 129
TABLE 199 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 129
TABLE 200 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 129
TABLE 201 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 130
TABLE 202 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 130
TABLE 203 U.S. AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 130
TABLE 204 U.S. AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 131
TABLE 205 CANADA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 131
TABLE 206 CANADA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 131
TABLE 207 CANADA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 132
TABLE 208 CANADA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 132
TABLE 209 CANADA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 132
TABLE 210 CANADA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 133
TABLE 211 CANADA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 133
TABLE 212 CANADA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 133
TABLE 213 CANADA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 134
TABLE 214 CANADA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 134
TABLE 215 CANADA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 134
TABLE 216 CANADA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 135
TABLE 217 CANADA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 135
TABLE 218 CANADA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 135
TABLE 219 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 136
TABLE 220 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 136
TABLE 221 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 136
TABLE 222 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 137
TABLE 223 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 137
TABLE 224 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 137
TABLE 225 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 138
TABLE 226 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 138
TABLE 227 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 138
TABLE 228 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 139
TABLE 229 CANADA AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 139
TABLE 230 CANADA AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 139
TABLE 231 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 140
TABLE 232 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 140
TABLE 233 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 140
TABLE 234 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 141
TABLE 235 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 141
TABLE 236 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 141
TABLE 237 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 142
TABLE 238 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 142
TABLE 239 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 142
TABLE 240 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 143
TABLE 241 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 143
TABLE 242 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 143
TABLE 243 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 143
TABLE 244 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 144
TABLE 245 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 144
TABLE 246 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 144
TABLE 247 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 145
TABLE 248 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 145
TABLE 249 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 145
TABLE 250 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 146
TABLE 251 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 146
TABLE 252 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 146
TABLE 253 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 147
TABLE 254 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 147
TABLE 255 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 147
TABLE 256 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 148
TABLE 257 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 148
TABLE 258 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 148
TABLE 259 EUROPE AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 149
TABLE 260 EUROPE AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 149
TABLE 261 . EUROPE AVASCULAR NECROSIS MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 149
TABLE 262 EUROPE AVASCULAR NECROSIS MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 150
TABLE 263 EUROPE AVASCULAR NECROSIS MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 150
TABLE 264 EUROPE AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 151
TABLE 265 EUROPE AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 151
TABLE 266 EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 151
TABLE 267 EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 152
TABLE 268 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 152
TABLE 269 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 152
TABLE 270 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 153
TABLE 271 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 153
TABLE 272 EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 153
TABLE 273 EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 154
TABLE 274 EUROPE AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 154
TABLE 275 EUROPE AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 154
TABLE 276 EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 155
TABLE 277 EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 155
TABLE 278 EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 155
TABLE 279 EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 156
TABLE 280 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 156
TABLE 281 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 156
TABLE 282 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 157
TABLE 283 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 157
TABLE 284 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 157
TABLE 285 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 158
TABLE 286 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 158
TABLE 287 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 158
TABLE 288 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 159
TABLE 289 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 159
TABLE 290 EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 159
TABLE 291 EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 160
TABLE 292 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 160
TABLE 293 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 160
TABLE 294 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 161
TABLE 295 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 161
TABLE 296 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 161
TABLE 297 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 162
TABLE 298 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 162
TABLE 299 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 162
TABLE 300 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 163
17 List Of Tables
TABLE 301 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 163
TABLE 302 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 163
TABLE 303 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 164
TABLE 304 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 164
TABLE 305 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 165
TABLE 306 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 165
TABLE 307 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 165
TABLE 308 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 166
TABLE 309 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 166
TABLE 310 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 166
TABLE 311 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 167
TABLE 312 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 167
TABLE 313 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 167
TABLE 314 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 168
TABLE 315 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 168
TABLE 316 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 168
TABLE 317 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 169
TABLE 318 GERMANY AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 170
TABLE 319 GERMANY AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 170
TABLE 320 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 170
TABLE 321 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 171
TABLE 322 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 171
TABLE 323 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 171
TABLE 324 GERMANY AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 172
TABLE 325 GERMANY AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 172
TABLE 326 GERMANY AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 172
TABLE 327 GERMANY AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 172
TABLE 328 GERMANY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 173
TABLE 329 GERMANY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 173
TABLE 330 GERMANY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 173
TABLE 331 GERMANY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 174
TABLE 332 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 174
TABLE 333 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 174
TABLE 334 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 175
TABLE 335 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 175
TABLE 336 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 175
TABLE 337 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 176
TABLE 338 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 176
TABLE 339 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 176
TABLE 340 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 177
TABLE 341 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 177
TABLE 342 GERMANY AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 177
TABLE 343 GERMANY AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 178
TABLE 344 FRANCE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 179
TABLE 345 FRANCE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 179
TABLE 346 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 179
TABLE 347 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 180
TABLE 348 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 180
TABLE 349 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 180
TABLE 350 FRANCE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 181
TABLE 351 FRANCE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 181
TABLE 352 FRANCE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 181
TABLE 353 FRANCE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 181
TABLE 354 FRANCE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 182
TABLE 355 FRANCE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 182
TABLE 356 FRANCE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 182
TABLE 357 FRANCE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 183
TABLE 358 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 183
TABLE 359 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 183
TABLE 360 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 184
TABLE 361 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 184
TABLE 362 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 184
TABLE 363 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 185
TABLE 364 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 185
TABLE 365 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 185
TABLE 366 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 186
TABLE 367 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 186
TABLE 368 FRANCE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 186
TABLE 369 FRANCE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 187
TABLE 370 UK AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 188
TABLE 371 UK AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 188
TABLE 372 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 188
TABLE 373 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 189
TABLE 374 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 189
TABLE 375 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 189
TABLE 376 UK AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 190
TABLE 377 UK AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 190
TABLE 378 UK AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 190
TABLE 379 UK AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 190
TABLE 380 UK AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 191
TABLE 381 UK AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 191
TABLE 382 UK AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 191
TABLE 383 UK AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 192
TABLE 384 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 192
TABLE 385 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 192
TABLE 386 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 193
TABLE 387 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 193
TABLE 388 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 193
TABLE 389 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 194
TABLE 390 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 194
TABLE 391 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 194
TABLE 392 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 195
TABLE 393 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 195
TABLE 394 UK AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 195
TABLE 395 UK AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 196
TABLE 396 ITALY AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 197
TABLE 397 ITALY AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 197
TABLE 398 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 197
TABLE 399 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 198
TABLE 400 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 198
TABLE 401 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 198
TABLE 402 ITALY AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 199
TABLE 403 ITALY AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 199
TABLE 404 ITALY AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 199
TABLE 405 ITALY AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 199
TABLE 406 ITALY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 200
TABLE 407 ITALY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 200
TABLE 408 ITALY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 200
TABLE 409 ITALY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 201
TABLE 410 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 201
TABLE 411 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 201
TABLE 412 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 202
TABLE 413 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 202
TABLE 414 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 202
TABLE 415 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 203
TABLE 416 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 203
TABLE 417 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 203
TABLE 418 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 204
TABLE 419 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 204
TABLE 420 ITALY AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 204
TABLE 421 ITALY AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 205
TABLE 422 SPAIN AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 206
TABLE 423 SPAIN AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 206
TABLE 424 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 206
TABLE 425 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 207
TABLE 426 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 207
TABLE 427 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 207
TABLE 428 SPAIN AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 208
TABLE 429 SPAIN AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 208
TABLE 430 SPAIN AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 208
TABLE 431 SPAIN AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 208
TABLE 432 SPAIN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 209
TABLE 433 SPAIN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 209
TABLE 434 SPAIN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 209
TABLE 435 SPAIN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 210
TABLE 436 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 210
TABLE 437 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 210
TABLE 438 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 211
TABLE 439 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 211
TABLE 440 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 211
TABLE 441 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 212
TABLE 442 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 212
TABLE 443 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 212
TABLE 444 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 213
TABLE 445 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 213
TABLE 446 SPAIN AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 213
TABLE 447 SPAIN AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 214
TABLE 448 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 215
TABLE 449 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 215
TABLE 450 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 215
TABLE 451 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 216
TABLE 452 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 216
TABLE 453 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 216
TABLE 454 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 217
TABLE 455 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 217
TABLE 456 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 217
TABLE 457 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 217
TABLE 458 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 218
TABLE 459 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 218
TABLE 460 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 218
TABLE 461 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 219
TABLE 462 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 219
TABLE 463 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 219
TABLE 464 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 220
TABLE 465 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 220
TABLE 466 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 220
TABLE 467 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 221
TABLE 468 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 221
TABLE 469 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 221
TABLE 470 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 222
TABLE 471 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 222
TABLE 472 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 222
TABLE 473 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 223
TABLE 474 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 224
TABLE 475 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 224
TABLE 476 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 224
TABLE 477 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 225
TABLE 478 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 225
TABLE 479 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 225
TABLE 480 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 226
TABLE 481 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 226
TABLE 482 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 226
TABLE 483 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 226
TABLE 484 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 227
TABLE 485 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 227
TABLE 486 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 227
TABLE 487 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 228
TABLE 488 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 228
TABLE 489 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 228
TABLE 490 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 229
TABLE 491 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 229
TABLE 492 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 229
TABLE 493 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 230
TABLE 494 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 230
TABLE 495 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 230
TABLE 496 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 231
TABLE 497 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 231
TABLE 498 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 231
TABLE 499 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 232
TABLE 500 . ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 232
TABLE 501 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 232
TABLE 502 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 233
TABLE 503 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 233
TABLE 504 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 234
TABLE 505 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 234
TABLE 506 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 234
TABLE 507 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 235
TABLE 508 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 235
TABLE 509 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 235
TABLE 510 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 236
TABLE 511 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 236
TABLE 512 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 236
TABLE 513 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 237
TABLE 514 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 237
TABLE 515 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 237
TABLE 516 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 238
TABLE 517 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 238
TABLE 518 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 238
TABLE 519 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 239
TABLE 520 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 239
TABLE 521 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 239
TABLE 522 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 240
TABLE 523 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 240
TABLE 524 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 240
TABLE 525 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 241
TABLE 526 ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 241
TABLE 527 ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 241
TABLE 528 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 242
TABLE 529 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 242
TABLE 530 . JAPAN AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 243
TABLE 531 JAPAN AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 243
TABLE 532 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 243
TABLE 533 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 244
TABLE 534 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 244
TABLE 535 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 244
TABLE 536 JAPAN AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 245
TABLE 537 JAPAN AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 245
TABLE 538 JAPAN AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 245
TABLE 539 JAPAN AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 245
TABLE 540 JAPAN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 246
TABLE 541 JAPAN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 246
TABLE 542 JAPAN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 246
TABLE 543 JAPAN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 247
TABLE 544 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 247
TABLE 545 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 247
TABLE 546 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 248
TABLE 547 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 248
TABLE 548 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 248
TABLE 549 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 249
TABLE 550 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 249
TABLE 551 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 249
TABLE 552 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 250
TABLE 553 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 250
TABLE 554 JAPAN AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 250
TABLE 555 JAPAN AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 251
TABLE 556 .CHINA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 251
TABLE 557 CHINA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 251
TABLE 558 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 252
TABLE 559 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 252
TABLE 560 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 252
TABLE 561 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 253
TABLE 562 CHINA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 253
TABLE 563 CHINA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 253
TABLE 564 CHINA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 254
TABLE 565 CHINA AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 254
TABLE 566 CHINA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 254
TABLE 567 CHINA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 255
TABLE 568 CHINA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 255
TABLE 569 CHINA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 255
TABLE 570 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 256
TABLE 571 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 256
TABLE 572 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 256
TABLE 573 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 257
TABLE 574 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 257
TABLE 575 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 257
TABLE 576 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 258
TABLE 577 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 258
TABLE 578 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 258
TABLE 579 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 259
TABLE 580 CHINA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 259
TABLE 581 CHINA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 259
TABLE 582 .INDIA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 260
TABLE 583 INDIA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 260
TABLE 584 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 260
TABLE 585 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 261
TABLE 586 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 261
TABLE 587 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 261
TABLE 588 INDIA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 262
TABLE 589 INDIA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 262
TABLE 590 INDIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 262
TABLE 591 INDIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2023-2032 (USD MILLION) 262
TABLE 592 INDIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 263
TABLE 593 INDIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 263
TABLE 594 INDIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 263
TABLE 595 INDIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 264
TABLE 596 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 264
TABLE 597 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 264
TABLE 598 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 265
TABLE 599 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 265
TABLE 600 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 265
18 List Of Tables
TABLE 601 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 266
TABLE 602 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 266
TABLE 603 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 266
TABLE 604 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 267
TABLE 605 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 267
TABLE 606 INDIA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 267
TABLE 607 INDIA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 268
TABLE 608 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 268
TABLE 609 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 268
TABLE 610 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 269
TABLE 611 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 269
TABLE 612 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 269
TABLE 613 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 270
TABLE 614 AUSTRALIA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 270
TABLE 615 AUSTRALIA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 270
TABLE 616 AUSTRALIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 271
TABLE 617 AUSTRALIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2023-2032 (USD MILLION) 271
TABLE 618 AUSTRALIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 271
TABLE 619 AUSTRALIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 272
TABLE 620 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 272
TABLE 621 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 272
TABLE 622 AUSTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 273
TABLE 623 AUSTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 273
TABLE 624 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 273
TABLE 625 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 274
TABLE 626 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 274
TABLE 627 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 274
TABLE 628 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 275
TABLE 629 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 275
TABLE 630 AUSTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 275
TABLE 631 USTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 276
TABLE 632 AUSTRALIA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 276
TABLE 633 AUSTRALIA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 276
TABLE 634 .REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 277
TABLE 635 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 277
TABLE 636 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 277
TABLE 637 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 278
TABLE 638 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 278
TABLE 639 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 278
TABLE 640 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 279
TABLE 641 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 279
TABLE 642 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 279
TABLE 643 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 279
TABLE 644 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 280
TABLE 645 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 280
TABLE 646 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 280
TABLE 647 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 281
TABLE 648 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 281
TABLE 649 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 281
TABLE 650 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 282
TABLE 651 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 282
TABLE 652 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 282
TABLE 653 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 283
TABLE 654 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 283
TABLE 655 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 283
TABLE 656 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 284
TABLE 657 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 284
TABLE 658 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 284
TABLE 659 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 285
TABLE 660 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 285
TABLE 661 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 285
TABLE 662 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 286
TABLE 663 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 286
TABLE 664 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 286
TABLE 665 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 287
TABLE 666 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 287
TABLE 667 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 287
TABLE 668 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 288
TABLE 669 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 288
TABLE 670 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 288
TABLE 671 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 289
TABLE 672 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 289
TABLE 673 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 289
TABLE 674 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 290
TABLE 675 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 290
TABLE 676 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 290
TABLE 677 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 291
TABLE 678 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 291
TABLE 679 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 291
TABLE 680 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 292
TABLE 681 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 292
TABLE 682 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 292
TABLE 683 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 293
TABLE 684 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 293
TABLE 685 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 293
TABLE 686 . MIDDLE EAST & AFRICA AVASCULAR NECROSIS MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 294
TABLE 687 MIDDLE EAST & AFRICA AVASCULAR NECROSIS MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 294
TABLE 688 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 295
TABLE 689 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 295
TABLE 690 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 295
TABLE 691 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 296
TABLE 692 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 296
TABLE 693 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 296
TABLE 694 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 297
TABLE 695 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 297
TABLE 696 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 297
TABLE 697 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 297
TABLE 698 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 298
TABLE 699 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 298
TABLE 700 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 298
TABLE 701 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 299
TABLE 702 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 299
TABLE 703 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 299
TABLE 704 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 300
TABLE 705 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 300
TABLE 706 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 300
TABLE 707 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 301
TABLE 708 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 301
TABLE 709 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 301
TABLE 710 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 302
TABLE 711 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 302
TABLE 712 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 302
TABLE 713 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 303
TABLE 714 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 303
TABLE 715 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 303
TABLE 716 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 304
TABLE 717 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 304
TABLE 718 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 305
TABLE 719 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 305
TABLE 720 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 305
TABLE 721 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 306
TABLE 722 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 306
TABLE 723 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 307
TABLE 724 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 307
TABLE 725 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 307
TABLE 726 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 307
TABLE 727 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2023-2032 (USD MILLION) 308
TABLE 728 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 308
TABLE 729 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 308
TABLE 730 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 309
TABLE 731 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 309
TABLE 732 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 309
TABLE 733 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 310
TABLE 734 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 310
TABLE 735 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 310
TABLE 736 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 311
TABLE 737 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 311
TABLE 738 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 311
TABLE 739 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 312
TABLE 740 MIDDLE EAST AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 312
TABLE 741 MIDDLE EAST AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 312
TABLE 742 AFRICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 313
TABLE 743 AFRICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 313
TABLE 744 .AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 314
TABLE 745 AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 314
TABLE 746 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 314
TABLE 747 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2023-2032 (USD MILLION) 315
TABLE 748 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 315
TABLE 749 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2023-2032 (USD MILLION) 315
TABLE 750 AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 316
TABLE 751 AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 316
TABLE 752 AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 316
TABLE 753 AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 316
TABLE 754 AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 317
TABLE 755 AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2023-2032 (USD MILLION) 317
TABLE 756 AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 317
TABLE 757 AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 318
TABLE 758 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2023-2032 (USD MILLION) 318
TABLE 759 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2023-2032 (USD MILLION) 318
TABLE 760 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 319
TABLE 761 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2023-2032 (USD MILLION) 319
TABLE 762 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 319
TABLE 763 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 320
TABLE 764 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 320
TABLE 765 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 320
TABLE 766 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 321
TABLE 767 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 321
TABLE 768 AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 321
TABLE 769 AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2023-2032 (USD MILLION) 322
TABLE 770 GLOBAL AVASCULAR NECROSIS MARKET: KEY DEVELOPMENT 326
19 List Of Figures
FIGURE 1 GLOBAL AVASCULAR NECROSIS MARKET: MARKET STRUCTURE 33
FIGURE 2 RESEARCH PROCESS OF MRFR 35
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 38
FIGURE 4 DRO OF GLOBAL AVASCULAR NECROSIS MARKET 40
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL AVASCULAR NECROSIS MARKET 46
FIGURE 6 SUPPLY CHAIN: AVASCULAR NECROSIS MARKET 48
FIGURE 7 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2010, 2020, 2027 (USD MILLION) 55
FIGURE 8 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2010, 2020, 2027 (USD MILLION) 64
FIGURE 9 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS 2010, 2020, 2027 (USD MILLION) 69
FIGURE 10 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT 2010, 2020, 2027 (USD MILLIONS) 77
FIGURE 11 GLOBAL AVASCULAR NECROSIS MARKET, BY END-USER 2010, 2020, 2027 (USD MILLION) 88
FIGURE 12 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2020 & 2027 (USD MILLION) 94
FIGURE 13 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2020 & 2027 (USD MILLION) 103
FIGURE 14 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2020, 2027 (USD MILLION) 113
FIGURE 15 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY COUNTRY, 2010-2027 (USD MILLION) 233
FIGURE 16 MIDDLE EAST & AFRICA AVASCULAR NECROSIS MARKET, BY COUNTRY, 2010-2027 (USD MILLION) 294
FIGURE 17 GLOBAL AVASCULAR NECROSIS MARKET, MARKET SHARE ANALYSIS 2020 (%) 324
FIGURE 18 GLOBAL AVASCULAR NECROSIS MARKET COMPETITIVE LANDSCAPE (%) 325